ANTISUBSTITUTION LAW CONTROVERSY - SOLUTION

被引：8

作者：

STROM, BL

STOLLEY, PD

BROWN, TC

机构：

[1] MARYLAND STATE HOUSE DELEGATES, BALTIMORE, MD USA

[2] JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,ROOM 6108, 615 N WOLFE ST, BALTIMORE, MD 21205 USA

来源：

关键词：

D O I：

10.7326/0003-4819-81-2-254

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：254 / 258

页数：5

共 18 条

[1]

BOYD EM, 1971, RX B, V2, P101

[2]

DOWLING HF, 1970, MEDICINES MAN DEVELO

[3]

FEINBERG M, 1970, PHARM TIMES, V36, P42

[4]

FINGL E, 1970, PHARMACOLOGICAL BASI

[5]

PFLAG SC, 1972, MIL MED, V137, P321

[6] THERAPEUTIC EQUIVALENCY AND ANTISUBSTITUTION LAWS [J].

SCHIFFMAN, DO .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1973, 223 (05) :552-553

[7]

SIMMONS HE, 1972, CALIF PHARM, V20, P18

[8]

Wagner JG, 1971, BIOPHARMACEUTICS REL

[9]

1972, JAMA, V221, P711

[10]

1972, JAMA, V220, P853